"We found that female patients, Black patients, and patients with non-private insurance had a decreased odds of receiving opioids,” says Hailey Frye. Researchers from the University of Minnesota, ...

"Personally, I think monitoring and analyzing PSA kinetics is a great one because it's cheap and it's readily available,” says Dr Louise Kostos. “I think that's a really good question, because I think ...

The trial is assessing the safety and tolerability of adaptive radiation therapy with concurrent sacituzumab govitecan in patients with MIBC. In a recent interview, Laura Bukavina, MD, MPH, shared the ...

"This certainly does feel like the beginning of the light at the end of the tunnel coming out of the BCG shortage," says Chad A. Reichard, MD. The FDA recently authorized an Expanded Access Program ...

“Erectile dysfunction is a major issue that affects prostate cancer patients, but it also results in relationship issues,” explained lead author Daniel Galvão, PhD, of Edith Cowen University in ...

An expert discusses how the SunRISe-1 phase 2b trial, presented at the European Society for Medical Oncology 2024 Congress (ESMO 2024), evaluated TAR-200 alone and with cetrelimab in BCG-unresponsive, ...

Experts discuss the patient demographics and clinical trial design of the phase 2b SunRISe-1 study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 ...

“Identification of significant predictors [of upstaging] has improved our pre-op counseling," says Neeraja Tillu, MD. A long-term, multicenter analysis of patients undergoing robot-assisted radical ...

Experts briefly mention other ongoing phase 3 studies investigating TAR-200 for the treatment of non–muscle-invasive bladder cancer (NMIBC).

This bill would cut funds for research projects in disease states such as prostate cancer, bladder cancer, kidney cancer, and interstitial cystitis. Yesterday, March 11, 2025, the US House of ...

The 52-week study plans to enroll 16 patients across 4 sites in the US. A phase 1b/2a trial (NCT06596291) has been initiated to evaluate the safety, tolerability, and initial efficacy of the ...

“The main challenge at the moment is patients are being diagnosed with metastatic disease far earlier than they would have been otherwise, and therefore [are being] considered for combination systemic ...